Smith and Nephew's Bioventus JV now live
Medical devices maker Smith and Nephew said that its Bioventus joint venture with Essex Woodlands is now up and running.
Medical devices maker Smith and Nephew said that its Bioventus joint venture with Essex Woodlands is now up and running.
Essex Woodlands, a specialist healthcare growth equity and venture capital firm, pitched in with Smith & Nephew (S&N) to further develop the S&N's Biologics and Clinical Therapies division.
The alliance was announced at the beginning of the year but was subject to obtaining required regulatory approvals and satisfaction of other customary conditions.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Essex Woodlands owns 51% of Bioventus with the rest owned by S&N.
JH
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Paying the grandkids’ school fees could generate a shock IHT bill
Private school fees have soared as a result of the government’s VAT policy, meaning more grandparents are helping out – but what are the tax implications?
-
Number of savings deals hits record high – as interest rates slump to two-year low
Savers have more choice than ever when it comes to choosing a savings account or cash ISA. But, the interest rates on offer continue to fall. What’s next for the savings market?